Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.
Use of imatinib in the first-line treatment of children and adolescents with chronic myeloid leukaemia (CML) appears highly effective, yielding excellent response with tolerable side effects, according to the results of a single-arm phase III trial.
Use of bosutinib in the treatment of chronic myeloid leukaemia (CML) still proves to be more effective than imatinib, with a higher major molecular response rate, according to the 24-month follow-up data from the phase III BFORE* trial.
Vitamin C may halt the self-renewal of TET methylcytosine dioxygenase 2 (TET2)-deficient haematopoietic cells and suppress leukaemia progression, in addition to rendering the cells more susceptible to poly ADP ribose polymerase (PARP) inhibition, according to a study.
Nilotinib demonstrates potential in the first-line treatment of patients with chronic myeloid leukaemia, yielding sustained deep molecular response in a clinically significant percentage of patients, according to the results of the phase II ENESTfreedom trial. Importantly, nilotinib-treated patients may remain in treatment-free remission for up to 48 weeks after stopping nilotinib.
Individuals given the BCR-ABL1 tyrosine kinase inhibitor (TKI) imatinib as first-line therapy for chronic myeloid leukaemia (CML) had a high overall survival (OS) rate a decade after initiating therapy, according to long-term follow-up of the IRIS* study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Combination therapy with the MET inhibitor savolitinib and the EGFR inhibitor osimertinib showed robust and durable clinical responses among patients with EGFR-mutated and MET-amplified non-small-cell lung cancer (NSCLC), according to results of the phase Ib TATTON study presented at AACR 2019.
Omitting first-line chemotherapy for patients with metastatic HER2+ breast cancer treated with pertuzumab plus trastuzumab did not affect overall survival (OS) despite shorter progression-free survival (PFS), according to updated results of the phase II PERNETTA* trial.